Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
30
JNJ Quote, Financials, Valuation and Earnings
Last price:
$144.51
Seasonality move
:
2.09%
Day range:
$142.75 - $145.47
52-week range:
$142.75 - $168.85
Dividend yield:
3.36%
P/E ratio:
23.88x
P/S ratio:
4.00x
P/B ratio:
4.96x
Volume:
17.5M
Avg. volume:
8.8M
1-year change:
-5.74%
Market cap:
$347.8B
Revenue:
$85.2B
EPS (TTM):
$6.05
Analysts' Opinion
-
Consensus RatingJohnson & Johnson has received a consensus rating of Hold. The company's average rating is a Hold based on 8 Buy ratings, 13 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $172.53, Johnson & Johnson has an estimated upside of 20.63% from its current price of $144.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $155.00 representing 100% downside risk from its current price of $144.47.
Fair Value
-
According to the consensus of 21 analysts, Johnson & Johnson has 20.63% upside to fair value with a price target of $172.53 per share.
JNJ vs. S&P 500
-
Over the past 5 trading days, Johnson & Johnson has overperformed the S&P 500 by 0.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Johnson & Johnson does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Johnson & Johnson has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Johnson & Johnson reported revenues of $22.5B.
Earnings Growth
-
Johnson & Johnson earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Johnson & Johnson reported earnings per share of $1.11.
Enterprise value:
363.3B
EV / Invested capital:
3.43x
Price / LTM sales:
4.00x
EV / EBIT:
19.75x
EV / Revenue:
4.14x
PEG ratio (5yr expected):
0.05x
EV / Free cash flow:
19.10x
Price / Operating cash flow:
18.44x
Enterprise value / EBITDA:
14.15x
Gross Profit (TTM):
$60.6B
Return On Assets:
8.49%
Net Income Margin (TTM):
16.74%
Return On Equity:
20.88%
Return On Invested Capital:
14.07%
Operating Margin:
23.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $77.2B | $83.7B | $87.7B | $21.4B | $22.5B | |
| Gross Profit | $54B | $57.9B | $60.6B | $14.7B | $15.5B | |
| Operating Income | $19.1B | $23.9B | $22.8B | $6.2B | $5.3B | |
| EBITDA | $25.3B | $22.3B | $25.7B | $7.2B | $5.4B | |
| Diluted EPS | $7.18 | $13.47 | $6.05 | $10.21 | $1.11 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $57.6B | $59.9B | $65.2B | $53.7B | $53.2B | |
| Total Assets | $170.7B | $179.2B | $175.1B | $166.1B | $178.3B | |
| Current Liabilities | $38.8B | $44.6B | $45.5B | $44.4B | $51.8B | |
| Total Liabilities | $106.2B | $109B | $100.5B | $94.8B | $108.1B | |
| Total Equity | $64.5B | $70.3B | $74.6B | $71.2B | $70.2B | |
| Total Debt | $37.8B | $33.9B | $32B | $29.9B | $35.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $21.6B | $20.3B | $25.1B | $7.5B | $8B | |
| Cash From Investing | -$13.3B | -$2.3B | -$18.5B | $2.5B | -$3.1B | |
| Cash From Financing | -$14B | -$9.5B | -$6.4B | -$11.3B | -$9.9B | |
| Free Cash Flow | $17.7B | $15.7B | $19B | $6.5B | $5.7B | |
JNJ
Sector
Market Cap
$347.8B
$44.6M
Price % of 52-Week High
85.56%
45.71%
Dividend Yield
3.36%
0%
Shareholder Yield
4.11%
-0.68%
1-Year Price Total Return
-5.74%
-29.09%
Beta (5-Year)
0.505
0.772
Dividend yield:
3.36%
Annualized payout:
$4.70
Payout ratio:
79.71%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$145.32
200-day SMA
Sell
Level
$154.89
Bollinger Bands (100)
Sell
Level
152.86 - 164.82
Chaikin Money Flow
Buy
Level
999.6M
20-day SMA
Sell
Level
$149.69
Relative Strength Index (RSI14)
Sell
Level
32.06
ADX Line
Sell
Level
12.06
Williams %R
Buy
Level
-85.7261
50-day SMA
Sell
Level
$155.19
MACD (12, 26)
Sell
Level
-3.16
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
119.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (-0.2874)
Buy
Beneish M-Score
(Annual)
Level (-2.7072)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-2.0096)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Stock Forecast FAQ
In the current month, JNJ has received 8 Buy ratings 13 Hold ratings, and 0 Sell ratings. The JNJ average analyst price target in the past 3 months is $172.53.
-
Where Will Johnson & Johnson Stock Be In 1 Year?
According to analysts, the consensus estimate is that Johnson & Johnson share price will rise to $172.53 per share over the next 12 months.
-
What Do Analysts Say About Johnson & Johnson?
Analysts are divided on their view about Johnson & Johnson share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Johnson & Johnson is a Sell and believe this share price will drop from its current level to $155.00.
-
What Is Johnson & Johnson's Price Target?
The price target for Johnson & Johnson over the next 1-year time period is forecast to be $172.53 according to 21 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 13 analysts rate the stock a Hold.
-
Is JNJ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Johnson & Johnson is a Hold. 13 of 21 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of JNJ?
You can purchase shares of Johnson & Johnson via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Johnson & Johnson shares.
-
What Is The Johnson & Johnson Share Price Today?
Johnson & Johnson was last trading at $144.51 per share. This represents the most recent stock quote for Johnson & Johnson. Yesterday, Johnson & Johnson closed at $144.47 per share.
-
How To Buy Johnson & Johnson Stock Online?
In order to purchase Johnson & Johnson stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
